3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
12
Other hematologic neoplasm
5
Myeloid
4
Other neoplasm
2
Sarcoma
1
Plasma cell
1
Conditions
Dendritic Cell Sarcoma, Interdigitating
76
Sarcoma
72
Burkitt Lymphoma
59
Lymphoma
58
Precursor Cell Lymphoblastic Leukemia-Lymphoma
56
Lymphoma, Large B-Cell, Diffuse
54
Lymphoma, Non-Hodgkin
53
Lymphoma, Follicular
49
Lymphoma, Mantle-Cell
48
Leukemia
48
Lymphoma, Large-Cell, Immunoblastic
47
Leukemia, Lymphocytic, Chronic, B-Cell
46
Lymphoma, B-Cell, Marginal Zone
45
Leukemia, Myeloid, Acute
43
Hodgkin Disease
42
Myelodysplastic Syndromes
41
Multiple Myeloma
40
Recurrence
39
Leukemia, Myeloid, Chronic-Phase
32
Leukemia, Myeloid, Accelerated Phase
31
Blast Crisis
30
Neoplasms, Plasma Cell
28
Sarcoma, Ewing
25
Rhabdomyosarcoma
25
Osteosarcoma
24
Myeloproliferative Disorders
24
Neuroblastoma
23
Leukemia, Myelomonocytic, Chronic
21
Congenital Abnormalities
21
Melanoma
20
Interventions
pembrolizumab
1
imetelstat
1
fludarabine phosphate
1
beta-Glucans
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methotrexate
1
Filgrastim
1
Early Intervention, Educational
1
Drug Therapy
1
Dapsone
1
Cyclophosphamide
1
Busulfan
1
Antilymphocyte Serum
1
ARQ531
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Cyclophosphamide
×
Sarcoma
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts